Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
about
Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications.The immune system in irritable bowel syndromeIrritable Bowel Syndrome: Peripheral Mechanisms and Therapeutic ImplicationsSaccharomyces boulardii CNCM I-745 in different clinical conditions.Saccharomyces boulardii CNCM I-745 supplementation reduces gastrointestinal dysfunction in an animal model of IBS.Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome.
P2860
Treatment of diarrhea-predominant irritable bowel syndrome with mesalazine and/or Saccharomyces boulardii.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@en
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@nl
type
label
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@en
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@nl
prefLabel
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@en
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@nl
P2093
P2860
P1476
Treatment of diarrhea-predomin ...... nd/or Saccharomyces boulardii.
@en
P2093
Enio Chaves de Oliveira
Joffre Resende-Filho
José Roberto de Almeida
Mauro Bafutto
Michelle Bafutto Gomes Costa
Nayle Vilela Leite
P2860
P304
P356
10.1590/S0004-28032013000400012
P577
2013-10-01T00:00:00Z